Abstract Number: 2746 • 2014 ACR/ARHP Annual Meeting
The Importance of the Serum Visfatin Levels in Behcet’s Disease Patients
Background/Purpose: It’s a known fact that serum levels of the tumor necrosis factor Alfa (TNF-α) interleucin-6 (IL-6) and other proinflammatory cytokines which are released from…Abstract Number: 2747 • 2014 ACR/ARHP Annual Meeting
Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis
Background/Purpose: Behcet’s disease (BD) is a chronic, multisystemic vasculitis, pathogenesis of BD remains enigmatic. Diagnosis of BD is sometimes difficult, and until now, no specific…Abstract Number: 2748 • 2014 ACR/ARHP Annual Meeting
Microparticles May Play a Role in Causing Thrombosis in Behçet’s Syndrome and Act As a Biomarker for Risk Management
Background/Purpose Thrombosis occurs in 20% of patients with Behçet’s Syndrome (BS) and leads to significant morbidity. There is no robust association between thrombosis in BS…Abstract Number: 2749 • 2014 ACR/ARHP Annual Meeting
The Clinical Course of Acute Deep Vein Thrombosis of the Legs in Behçet’s Syndrome
Background/Purpose To determine the prospective clinical course of lower extremity deep vein thrombosis (LEDVT) in patients with Behçet’s syndrome (BS). Methods Consecutive BS patients with…Abstract Number: 2750 • 2014 ACR/ARHP Annual Meeting
Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet’s Disease with Vascular Involvement
Background/Purpose: Vascular involvement (VI) is one of the major causes of mortality and morbidity in Behcet's Disease (BD). There are no controlled studies for the…Abstract Number: 2751 • 2014 ACR/ARHP Annual Meeting
18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
Background/Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT is considered as a useful tool in assessing active vascular inflammation in large vessel vasculitis. Lower extremity vein…Abstract Number: 2752 • 2014 ACR/ARHP Annual Meeting
Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
Background/Purpose Behçet’s syndrome (BS) is a well recognized cause of Budd–Chiari syndrome (BCS), however, information about its clinical characteristics and outcome is limited. We had…Abstract Number: 2753 • 2014 ACR/ARHP Annual Meeting
Reduced Heart Rate Variability in Patients with Behcet’s Disease
Background/Purpose The autonomic nervous system, including the sympathetic and parasympathetic nervous systems, has an important role in the triggering of ventricular arrhythmias and sudden cardiac…Abstract Number: 2732 • 2014 ACR/ARHP Annual Meeting
Massive Ex Vivo Expansion of Functionally Stable Behcet’s Patient-Derived Regulatory T Cell Clones
Background/Purpose: Adoptive transfer of regulatory T cells (Treg) is a promising strategy for the treatment of human autoimmune diseases. Most currently tested approaches focus on…Abstract Number: 2731 • 2014 ACR/ARHP Annual Meeting
Th1 and Th17 Cytokines Drive Takayasu Arteritis Inflammation
Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis inducing damage of the aorta and its branches. Glucocorticoids remain the gold standard of therapy in TA.…Abstract Number: 2730 • 2014 ACR/ARHP Annual Meeting
FcγRIIIa Ligation in Human Peripheral CD4+ T-Cells Generate TH17 like Population
Background/Purpose: Cytokines produced during TH17 response, IL-17A and IL17F drive inflammation and autoimmunity. They also act as a bridge between adaptive and innate immunity. Immune…Abstract Number: 2728 • 2014 ACR/ARHP Annual Meeting
Reduction of MAIT Cell Frequency Associated with Reduced Cell Proliferation and Enhanced Cell Death in Systemic Lupus Erythematosus
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain: Vα7.2-Jα33 in…Abstract Number: 2729 • 2014 ACR/ARHP Annual Meeting
To Live or Let Die… the Battle Between PD-1 and OX40 on SLE T Cells
Background/Purpose: Programmed cell death 1 (PD-1) is a co-inhibitory receptor, which inhibits T cell proliferation and survival by inhibiting IL-2 signalling. By this PD-1 has…Abstract Number: 2727 • 2014 ACR/ARHP Annual Meeting
T Cells Trigger Interstitial Pneumonia in Polymyositis
Background/Purpose: The lung is frequently affected in connective tissue diseases (CTDs). Polymyositis (PM) is a major CTD characterized by idiopathic inflammatory lesions of muscle and…Abstract Number: 2726 • 2014 ACR/ARHP Annual Meeting
CD28null T Cells from Polymyositis Patients Are Cytotoxic to Autologous Muscle Cells in Vitro Via Perforin-Dependent Mechanisms
Background/Purpose: Inflammatory infiltrates of muscles in polymyositis are dominated by CD4+CD28null and CD8+CD28null T cells. In contrast to conventional CD28+ T cells, these cells…
ACR Meeting Abstracts